25 XP   0   0   10

Y mAbs Therapeutics
Buy, Hold or Sell?

Let's analyse Y mAbs Therapeutics together

PenkeI guess you are interested in Y mAbs Therapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Y mAbs Therapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Y mAbs Therapeutics

I send you an email if I find something interesting about Y mAbs Therapeutics.

Quick analysis of Y mAbs Therapeutics (30 sec.)










What can you expect buying and holding a share of Y mAbs Therapeutics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.31
Expected worth in 1 year
$2.17
How sure are you?
25.9%

+ What do you gain per year?

Total Gains per Share
$-0.14
Return On Investment
-0.9%

For what price can you sell your share?

Current Price per Share
$15.11
Expected price per share
$11.70 - $20.48
How sure are you?
50%

1. Valuation of Y mAbs Therapeutics (5 min.)




Live pricePrice per Share (EOD)

$15.11

Intrinsic Value Per Share

$-1.74 - $-1.41

Total Value Per Share

$0.57 - $0.90

2. Growth of Y mAbs Therapeutics (5 min.)




Is Y mAbs Therapeutics growing?

Current yearPrevious yearGrowGrow %
How rich?$100.9m$126.4m-$23m-22.3%

How much money is Y mAbs Therapeutics making?

Current yearPrevious yearGrowGrow %
Making money-$5m-$25m$20m397.6%
Net Profit Margin-24.4%-224.0%--

How much money comes from the company's main activities?

3. Financial Health of Y mAbs Therapeutics (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#376 / 1016

Most Revenue
#230 / 1016

Most Profit
#424 / 1016

Most Efficient
#508 / 1016

What can you expect buying and holding a share of Y mAbs Therapeutics? (5 min.)

Welcome investor! Y mAbs Therapeutics's management wants to use your money to grow the business. In return you get a share of Y mAbs Therapeutics.

What can you expect buying and holding a share of Y mAbs Therapeutics?

First you should know what it really means to hold a share of Y mAbs Therapeutics. And how you can make/lose money.

Speculation

The Price per Share of Y mAbs Therapeutics is $15.11. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Y mAbs Therapeutics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Y mAbs Therapeutics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.31. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.42 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Y mAbs Therapeutics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.02-0.1%-0.12-0.8%-0.55-3.6%-0.43-2.8%-0.38-2.5%
Usd Book Value Change Per Share0.020.1%-0.03-0.2%-0.42-2.8%-0.05-0.3%0.090.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.020.1%-0.03-0.2%-0.42-2.8%-0.05-0.3%0.090.6%
Usd Price Per Share6.82-6.02-11.58-22.14-18.14-
Price to Earnings Ratio-75.55--25.90-8.18--10.71--9.46-
Price-to-Total Gains Ratio357.56-117.50--77.24--26.54--26.33-
Price to Book Ratio2.96-2.55-4.05-7.05-5.74-
Price-to-Total Gains Ratio357.56-117.50--77.24--26.54--26.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15.11
Number of shares66
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.03-0.05
Usd Total Gains Per Share-0.03-0.05
Gains per Quarter (66 shares)-2.26-2.98
Gains per Year (66 shares)-9.04-11.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9-190-12-22
20-18-280-24-34
30-27-370-36-46
40-36-460-48-58
50-45-550-60-70
60-54-640-72-82
70-63-730-83-94
80-72-820-95-106
90-81-910-107-118
100-90-1000-119-130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%2.025.00.07.4%2.025.00.07.4%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%7.018.02.025.9%7.018.02.025.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.027.00.0%0.00.027.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%7.018.02.025.9%7.018.02.025.9%

Fundamentals of Y mAbs Therapeutics

About Y mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-04-12 22:47:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Y mAbs Therapeutics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Y mAbs Therapeutics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Y mAbs Therapeutics to the Biotechnology industry mean.
  • A Net Profit Margin of -4.2% means that $-0.04 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Y mAbs Therapeutics:

  • The MRQ is -4.2%. The company is making a loss. -1
  • The TTM is -24.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4.2%TTM-24.4%+20.2%
TTM-24.4%YOY-224.0%+199.6%
TTM-24.4%5Y-69.2%+44.8%
5Y-69.2%10Y-51.3%-18.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.2%-197.2%+193.0%
TTM-24.4%-210.4%+186.0%
YOY-224.0%-279.3%+55.3%
5Y-69.2%-436.8%+367.6%
10Y-51.3%-599.3%+548.0%
1.1.2. Return on Assets

Shows how efficient Y mAbs Therapeutics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Y mAbs Therapeutics to the Biotechnology industry mean.
  • -0.8% Return on Assets means that Y mAbs Therapeutics generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Y mAbs Therapeutics:

  • The MRQ is -0.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.8%TTM-3.8%+3.0%
TTM-3.8%YOY-15.2%+11.4%
TTM-3.8%5Y-11.9%+8.1%
5Y-11.9%10Y-14.5%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.8%-13.6%+12.8%
TTM-3.8%-12.9%+9.1%
YOY-15.2%-11.9%-3.3%
5Y-11.9%-14.2%+2.3%
10Y-14.5%-16.2%+1.7%
1.1.3. Return on Equity

Shows how efficient Y mAbs Therapeutics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Y mAbs Therapeutics to the Biotechnology industry mean.
  • -1.0% Return on Equity means Y mAbs Therapeutics generated $-0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Y mAbs Therapeutics:

  • The MRQ is -1.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.0%TTM-4.9%+3.9%
TTM-4.9%YOY-19.4%+14.5%
TTM-4.9%5Y-14.3%+9.4%
5Y-14.3%10Y-18.0%+3.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.0%-17.0%+16.0%
TTM-4.9%-16.1%+11.2%
YOY-19.4%-15.4%-4.0%
5Y-14.3%-20.0%+5.7%
10Y-18.0%-21.1%+3.1%

1.2. Operating Efficiency of Y mAbs Therapeutics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Y mAbs Therapeutics is operating .

  • Measures how much profit Y mAbs Therapeutics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Y mAbs Therapeutics to the Biotechnology industry mean.
  • An Operating Margin of -13.7% means the company generated $-0.14  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Y mAbs Therapeutics:

  • The MRQ is -13.7%. The company is operating very inefficient. -2
  • The TTM is -31.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-13.7%TTM-31.6%+17.9%
TTM-31.6%YOY-211.5%+179.9%
TTM-31.6%5Y-124.5%+92.9%
5Y-124.5%10Y-92.2%-32.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.7%-286.1%+272.4%
TTM-31.6%-224.4%+192.8%
YOY-211.5%-288.4%+76.9%
5Y-124.5%-475.2%+350.7%
10Y-92.2%-624.7%+532.5%
1.2.2. Operating Ratio

Measures how efficient Y mAbs Therapeutics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.14 means that the operating costs are $1.14 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Y mAbs Therapeutics:

  • The MRQ is 1.137. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.309. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.137TTM1.309-0.172
TTM1.309YOY3.113-1.805
TTM1.3095Y2.229-0.920
5Y2.22910Y1.651+0.578
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1372.997-1.860
TTM1.3093.247-1.938
YOY3.1133.766-0.653
5Y2.2295.675-3.446
10Y1.6517.857-6.206

1.3. Liquidity of Y mAbs Therapeutics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Y mAbs Therapeutics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.52 means the company has $5.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Y mAbs Therapeutics:

  • The MRQ is 5.520. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.087. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.520TTM5.087+0.433
TTM5.087YOY5.030+0.057
TTM5.0875Y8.274-3.187
5Y8.27410Y9.401-1.127
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5203.930+1.590
TTM5.0874.251+0.836
YOY5.0305.436-0.406
5Y8.2746.045+2.229
10Y9.4016.363+3.038
1.3.2. Quick Ratio

Measures if Y mAbs Therapeutics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Y mAbs Therapeutics to the Biotechnology industry mean.
  • A Quick Ratio of 5.02 means the company can pay off $5.02 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Y mAbs Therapeutics:

  • The MRQ is 5.022. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.642. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.022TTM4.642+0.380
TTM4.642YOY4.637+0.005
TTM4.6425Y7.933-3.291
5Y7.93310Y8.003-0.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0223.629+1.393
TTM4.6424.065+0.577
YOY4.6375.397-0.760
5Y7.9335.993+1.940
10Y8.0036.277+1.726

1.4. Solvency of Y mAbs Therapeutics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Y mAbs Therapeutics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Y mAbs Therapeutics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.21 means that Y mAbs Therapeutics assets are financed with 21.0% credit (debt) and the remaining percentage (100% - 21.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Y mAbs Therapeutics:

  • The MRQ is 0.210. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.215. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.210TTM0.215-0.004
TTM0.215YOY0.2150.000
TTM0.2155Y0.164+0.051
5Y0.16410Y0.154+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2100.332-0.122
TTM0.2150.334-0.119
YOY0.2150.268-0.053
5Y0.1640.366-0.202
10Y0.1540.390-0.236
1.4.2. Debt to Equity Ratio

Measures if Y mAbs Therapeutics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Y mAbs Therapeutics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 26.6% means that company has $0.27 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Y mAbs Therapeutics:

  • The MRQ is 0.266. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.273. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.266TTM0.273-0.007
TTM0.273YOY0.275-0.002
TTM0.2735Y0.201+0.073
5Y0.20110Y0.187+0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2660.381-0.115
TTM0.2730.390-0.117
YOY0.2750.334-0.059
5Y0.2010.434-0.233
10Y0.1870.466-0.279

2. Market Valuation of Y mAbs Therapeutics

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Y mAbs Therapeutics generates.

  • Above 15 is considered overpriced but always compare Y mAbs Therapeutics to the Biotechnology industry mean.
  • A PE ratio of -75.55 means the investor is paying $-75.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Y mAbs Therapeutics:

  • The EOD is -167.377. Based on the earnings, the company is expensive. -2
  • The MRQ is -75.547. Based on the earnings, the company is expensive. -2
  • The TTM is -25.905. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-167.377MRQ-75.547-91.830
MRQ-75.547TTM-25.905-49.642
TTM-25.905YOY8.184-34.088
TTM-25.9055Y-10.708-15.197
5Y-10.70810Y-9.460-1.248
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-167.377-2.315-165.062
MRQ-75.547-2.560-72.987
TTM-25.905-2.664-23.241
YOY8.184-4.122+12.306
5Y-10.708-6.258-4.450
10Y-9.460-6.108-3.352
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Y mAbs Therapeutics:

  • The EOD is -20.578. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.288. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -18.436. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.578MRQ-9.288-11.290
MRQ-9.288TTM-18.436+9.147
TTM-18.436YOY-6.721-11.714
TTM-18.4365Y-14.833-3.602
5Y-14.83310Y-12.757-2.076
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.578-3.067-17.511
MRQ-9.288-3.251-6.037
TTM-18.436-3.545-14.891
YOY-6.721-5.595-1.126
5Y-14.833-8.315-6.518
10Y-12.757-8.708-4.049
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Y mAbs Therapeutics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.96 means the investor is paying $2.96 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Y mAbs Therapeutics:

  • The EOD is 6.550. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.956. Based on the equity, the company is underpriced. +1
  • The TTM is 2.553. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD6.550MRQ2.956+3.594
MRQ2.956TTM2.553+0.403
TTM2.553YOY4.048-1.495
TTM2.5535Y7.055-4.502
5Y7.05510Y5.738+1.317
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.5501.905+4.645
MRQ2.9562.111+0.845
TTM2.5532.095+0.458
YOY4.0482.836+1.212
5Y7.0553.443+3.612
10Y5.7383.794+1.944
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Y mAbs Therapeutics.

3.1. Institutions holding Y mAbs Therapeutics

Institutions are holding 61.882% of the shares of Y mAbs Therapeutics.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc6.66350.0005291708044372417.9402
2023-12-31Vanguard Group Inc5.12650.00032244238123300.5524
2023-12-31Sofinnova Ventures5.01240.8374219427800
2023-12-31Polar Capital Holdings PLC4.69850.08592056872-46426-2.2073
2023-09-30D. E. Shaw & Co LP3.0820.00771349210738135.7875
2023-12-31Caligan Partners LP2.39492.4114104842510251044395.6263
2023-12-31Acadian Asset Management LLC1.83290.0212802381-8880-1.0946
2023-12-31Goldman Sachs Group Inc1.81810.0005795902406555104.4197
2023-12-31State Street Corporation1.73960.0003761532204342.7573
2023-12-31Geode Capital Management, LLC1.68710.0005738548277153.8989
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC1.58550.12086940946785484364.7755
2023-09-30Jacobs Levy Equity Management, Inc.1.21170.0171530439-34092-6.039
2023-09-30Citadel Advisors Llc0.94640.00054143073827941214.7177
2023-12-31Nuveen Asset Management, LLC0.91360.00093999404154111.5907
2023-12-31Los Angeles Capital Management LLC0.81440.00913565305261017.3105
2023-12-31Northern Trust Corp0.74340.000432543922520.6968
2023-12-31Dimensional Fund Advisors, Inc.0.71520.00063131017151229.6007
2023-12-31Charles Schwab Investment Management Inc0.56540.0004247506-1938-0.7769
2023-12-31Morgan Stanley - Brokerage Accounts0.560.0002245145137271127.2512
2023-09-30Memorial Sloan-kettering Cancer Center0.43674.242519117600
Total 42.54787.758218626143+3284867+17.6%

3.2. Funds holding Y mAbs Therapeutics

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31HBM Healthcare Investments AG Ord7.53321.1265329780000
2024-02-29Polar Capital Biotech S Inc3.94041.6382172500000
2024-02-29Vanguard Total Stock Mkt Idx Inv2.64790.0013115917800
2024-02-29iShares Russell 2000 ETF2.06850.0243905508-148-0.0163
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.04080.0075455652-4598-0.999
2023-12-31Fidelity Small Cap Index0.84460.009936973536901.0081
2024-02-29iShares Biotechnology ETF0.58920.0566257926-1160-0.4477
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.51050.008922349336001.6372
2024-02-01iShares Russell 2000 Value ETF0.40670.02021780482260.1271
2024-01-31CREF Stock R10.38370.0018167990-80580-32.4174
2024-01-31Fidelity Extended Market Index0.37260.005816310200
2024-02-29iShares Russell 2000 Growth ETF0.35650.023156054-181-0.1159
2023-12-31Vanguard Strategic Small-Cap Equity Inv0.3270.065614315500
2024-01-31DFA US Micro Cap I0.31220.025713667100
2024-02-29Schwab US Small-Cap ETF™0.3090.013513525200
2024-02-29Vanguard Russell 2000 ETF0.30790.0236134786103288.2984
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.30450.023613328200
2024-02-29Vanguard Health Care ETF0.27220.00951191506080.5129
2023-12-31Vanguard VIF Small Co Gr0.23620.046610340400
2023-12-31NT R2000 Index Fund - NL0.2320.0096101551-6892-6.3554
Total 22.99563.141710066737-75107-0.7%

3.3. Insider Transactions

Insiders are holding 14.545% of the shares of Y mAbs Therapeutics.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-05Vignesh RajahSELL171116.53
2023-12-15Thomas GadSELL500006.61
2023-12-13Thomas GadSELL500006.58
2023-12-11Biotech Aps WgBUY1028637.01
2023-12-07Biotech Aps WgBUY61836.5
2023-11-29Biotech Aps WgBUY518375.97
2023-11-27Johan Wedell-wedellsborgBUY625165.49
2023-11-20Thomas GadSELL750005.3
2023-05-15Johan Wedell-wedellsborgBUY1017409.65

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Y mAbs Therapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.019-0.034+280%-0.418+2289%-0.045+337%0.085-78%
Book Value Per Share--2.3072.362-2%2.877-20%3.258-29%2.923-21%
Current Ratio--5.5205.087+9%5.030+10%8.274-33%9.401-41%
Debt To Asset Ratio--0.2100.215-2%0.215-2%0.164+28%0.154+37%
Debt To Equity Ratio--0.2660.273-3%0.275-3%0.201+33%0.187+42%
Dividend Per Share----0%-0%-0%-0%
Eps---0.023-0.122+442%-0.546+2319%-0.426+1787%-0.381+1590%
Free Cash Flow Per Share---0.184-0.156-15%-0.433+136%-0.426+132%-0.368+100%
Free Cash Flow To Equity Per Share---0.181-0.155-15%-0.432+138%-0.149-18%0.004-4547%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.407--------
Intrinsic Value_10Y_min---1.740--------
Intrinsic Value_1Y_max---1.364--------
Intrinsic Value_1Y_min---1.341--------
Intrinsic Value_3Y_max---3.167--------
Intrinsic Value_3Y_min---3.042--------
Intrinsic Value_5Y_max---3.845--------
Intrinsic Value_5Y_min---3.649--------
Market Cap661471981.000+55%298559822.000263428699.250+13%507946144.950-41%971779974.103-69%795879461.928-62%
Net Profit Margin---0.042-0.244+477%-2.240+5197%-0.692+1537%-0.513+1113%
Operating Margin---0.137-0.316+130%-2.115+1445%-1.245+809%-0.922+573%
Operating Ratio--1.1371.309-13%3.113-63%2.229-49%1.651-31%
Pb Ratio6.550+55%2.9562.553+16%4.048-27%7.055-58%5.738-48%
Pe Ratio-167.377-122%-75.547-25.905-66%8.184-1023%-10.708-86%-9.460-87%
Price Per Share15.110+55%6.8206.018+13%11.578-41%22.138-69%18.136-62%
Price To Free Cash Flow Ratio-20.578-122%-9.288-18.436+98%-6.721-28%-14.833+60%-12.757+37%
Price To Total Gains Ratio792.182+55%357.557117.504+204%-77.241+122%-26.540+107%-26.327+107%
Quick Ratio--5.0224.642+8%4.637+8%7.933-37%8.003-37%
Return On Assets---0.008-0.038+393%-0.152+1873%-0.119+1436%-0.145+1773%
Return On Equity---0.010-0.049+397%-0.194+1881%-0.143+1362%-0.180+1739%
Total Gains Per Share--0.019-0.034+280%-0.418+2289%-0.045+337%0.085-78%
Usd Book Value--100985000.000103411250.000-2%126496750.000-20%142976950.000-29%128240777.778-21%
Usd Book Value Change Per Share--0.019-0.034+280%-0.418+2289%-0.045+337%0.085-78%
Usd Book Value Per Share--2.3072.362-2%2.877-20%3.258-29%2.923-21%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.023-0.122+442%-0.546+2319%-0.426+1787%-0.381+1590%
Usd Free Cash Flow---8036000.000-6808000.000-15%-18980250.000+136%-18677200.000+132%-16125740.741+101%
Usd Free Cash Flow Per Share---0.184-0.156-15%-0.433+136%-0.426+132%-0.368+100%
Usd Free Cash Flow To Equity Per Share---0.181-0.155-15%-0.432+138%-0.149-18%0.004-4547%
Usd Market Cap661471981.000+55%298559822.000263428699.250+13%507946144.950-41%971779974.103-69%795879461.928-62%
Usd Price Per Share15.110+55%6.8206.018+13%11.578-41%22.138-69%18.136-62%
Usd Profit---988000.000-5033500.000+409%-25048500.000+2435%-18798400.000+1803%-16643703.704+1585%
Usd Revenue--23363000.00021204750.000+10%16316750.000+43%10286650.000+127%7619740.741+207%
Usd Total Gains Per Share--0.019-0.034+280%-0.418+2289%-0.045+337%0.085-78%
 EOD+6 -2MRQTTM+22 -11YOY+27 -65Y+20 -1310Y+16 -17

4.2. Fundamental Score

Let's check the fundamental score of Y mAbs Therapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-167.377
Price to Book Ratio (EOD)Between0-16.550
Net Profit Margin (MRQ)Greater than0-0.042
Operating Margin (MRQ)Greater than0-0.137
Quick Ratio (MRQ)Greater than15.022
Current Ratio (MRQ)Greater than15.520
Debt to Asset Ratio (MRQ)Less than10.210
Debt to Equity Ratio (MRQ)Less than10.266
Return on Equity (MRQ)Greater than0.15-0.010
Return on Assets (MRQ)Greater than0.05-0.008
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Y mAbs Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.543
Ma 20Greater thanMa 5015.185
Ma 50Greater thanMa 10015.568
Ma 100Greater thanMa 20011.811
OpenGreater thanClose15.140
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets127,869
Total Liabilities26,884
Total Stockholder Equity100,985
 As reported
Total Liabilities 26,884
Total Stockholder Equity+ 100,985
Total Assets = 127,869

Assets

Total Assets127,869
Total Current Assets111,111
Long-term Assets16,758
Total Current Assets
Cash And Cash Equivalents 78,637
Net Receivables 22,454
Inventory 5,065
Other Current Assets 4,955
Total Current Assets  (as reported)111,111
Total Current Assets  (calculated)111,111
+/-0
Long-term Assets
Property Plant Equipment 1,636
Intangible Assets 2,631
Long-term Assets Other 12,491
Long-term Assets  (as reported)16,758
Long-term Assets  (calculated)16,758
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,128
Long-term Liabilities6,756
Total Stockholder Equity100,985
Total Current Liabilities
Short-term Debt 902
Accounts payable 6,060
Other Current Liabilities 13,166
Total Current Liabilities  (as reported)20,128
Total Current Liabilities  (calculated)20,128
+/-0
Long-term Liabilities
Capital Lease Obligations 1,419
Long-term Liabilities Other 864
Long-term Liabilities  (as reported)6,756
Long-term Liabilities  (calculated)2,283
+/- 4,473
Total Stockholder Equity
Common Stock4
Retained Earnings -457,470
Accumulated Other Comprehensive Income 449
Other Stockholders Equity 558,002
Total Stockholder Equity (as reported)100,985
Total Stockholder Equity (calculated)100,985
+/-0
Other
Capital Stock4
Cash and Short Term Investments 78,637
Common Stock Shares Outstanding 43,627
Liabilities and Stockholders Equity 127,869
Net Debt -77,218
Net Invested Capital 100,985
Net Working Capital 90,983
Property Plant and Equipment Gross 1,636
Short Long Term Debt Total 1,419



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-12-31
> Total Assets 
17,261
92,127
92,127
73,298
73,298
166,394
151,924
139,997
126,040
103,684
216,366
194,074
167,329
143,195
132,047
274,916
259,479
239,979
212,783
191,047
165,178
143,915
141,456
137,445
132,396
128,884
127,869
127,869128,884132,396137,445141,456143,915165,178191,047212,783239,979259,479274,916132,047143,195167,329194,074216,366103,684126,040139,997151,924166,39473,29873,29892,12792,12717,261
   > Total Current Assets 
17,261
91,355
91,355
71,729
71,729
166,044
151,532
137,034
123,190
99,591
211,955
189,836
163,320
133,209
122,363
264,009
249,369
230,580
202,261
177,739
153,920
133,244
130,447
124,006
115,784
114,860
111,111
111,111114,860115,784124,006130,447133,244153,920177,739202,261230,580249,369264,009122,363133,209163,320189,836211,95599,591123,190137,034151,532166,04471,72971,72991,35591,35517,261
       Cash And Cash Equivalents 
16,875
90,483
90,483
70,152
70,152
163,292
147,840
134,245
120,163
98,192
207,136
185,774
158,059
131,267
114,634
252,271
233,587
215,730
181,564
156,724
133,665
114,526
105,762
92,629
87,909
86,571
78,637
78,63786,57187,90992,629105,762114,526133,665156,724181,564215,730233,587252,271114,634131,267158,059185,774207,13698,192120,163134,245147,840163,29270,15270,15290,48390,48316,875
       Short-term Investments 
28
0
32
0
31
31
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000003131032028
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
800
5,997
8,517
7,264
7,712
9,324
7,208
9,251
12,531
18,702
19,118
18,874
22,454
22,45418,87419,11818,70212,5319,2517,2089,3247,7127,2648,5175,99780000000000000000
       Other Current Assets 
358
872
840
1,577
1,546
2,721
3,661
2,759
3,027
1,399
4,819
4,062
5,261
1,942
7,729
4,736
3,445
2,799
7,473
6,103
6,253
3,225
5,452
3,730
3,570
2,302
4,955
4,9552,3023,5703,7305,4523,2256,2536,1037,4732,7993,4454,7367,7291,9425,2614,0624,8191,3993,0272,7593,6612,7211,5461,577840872358
   > Long-term Assets 
0
0
772
0
1,569
350
392
2,963
2,850
4,093
4,411
4,238
4,009
9,986
9,684
10,907
10,110
9,399
10,522
13,308
11,258
10,671
11,009
13,439
16,612
14,024
16,758
16,75814,02416,61213,43911,00910,67111,25813,30810,5229,39910,11010,9079,6849,9864,0094,2384,4114,0932,8502,9633923501,569077200
       Property Plant Equipment 
0
0
0
118
118
162
205
2,720
2,606
3,775
4,041
3,857
3,652
7,011
6,394
6,074
5,317
4,648
5,689
4,852
3,935
3,541
2,343
1,880
1,553
1,889
1,636
1,6361,8891,5531,8802,3433,5413,9354,8525,6894,6485,3176,0746,3947,0113,6523,8574,0413,7752,6062,720205162118118000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,663
1,618
1,574
1,530
2,986
2,898
2,809
2,720
2,631
2,6312,7202,8092,8982,9861,5301,5741,6181,663000000000000000000
       Other Assets 
0
772
772
1,451
1,451
188
187
243
244
318
370
381
357
2,975
7,859
3,033
4,793
4,751
206,911
6,838
5,749
5,600
5,680
8,661
12,250
0
0
0012,2508,6615,6805,6005,7496,838206,9114,7514,7933,0337,8592,9753573813703182442431871881,4511,4517727720
> Total Liabilities 
5,200
9,975
9,975
7,777
7,777
11,366
11,397
14,484
17,658
17,745
17,463
18,744
21,321
26,683
26,211
22,699
25,163
29,134
32,677
33,575
33,782
36,017
32,235
29,616
27,715
28,734
26,884
26,88428,73427,71529,61632,23536,01733,78233,57532,67729,13425,16322,69926,21126,68321,32118,74417,46317,74517,65814,48411,39711,3667,7777,7779,9759,9755,200
   > Total Current Liabilities 
2,975
7,925
7,925
5,727
5,727
9,316
9,123
10,301
13,628
13,992
13,586
14,843
15,707
19,777
19,535
17,000
20,986
25,359
27,875
29,042
29,450
32,015
28,284
25,920
24,233
21,812
20,128
20,12821,81224,23325,92028,28432,01529,45029,04227,87525,35920,98617,00019,53519,77715,70714,84313,58613,99213,62810,3019,1239,3165,7275,7277,9257,9252,975
       Short-term Debt 
0
0
0
0
0
0
0
517
502
516
516
548
569
1,887
1,966
1,971
2,014
1,849
1,783
1,451
1,092
1,200
868
855
829
898
902
9028988298558681,2001,0921,4511,7831,8492,0141,9711,9661,8875695485165165025170000000
       Short Long Term Debt 
0
0
0
0
0
0
0
517
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000005170000000
       Accounts payable 
2,227
5,909
5,909
4,242
4,242
6,827
5,872
5,907
8,911
7,628
8,520
10,260
9,825
10,320
9,372
6,543
6,803
11,024
13,552
14,661
11,291
13,723
14,175
8,843
7,252
7,610
6,060
6,0607,6107,2528,84314,17513,72311,29114,66113,55211,0246,8036,5439,37210,3209,82510,2608,5207,6288,9115,9075,8726,8274,2424,2425,9095,9092,227
       Other Current Liabilities 
748
0
2,016
0
1,485
2,489
3,251
517
4,215
5,848
4,550
4,035
5,313
7,570
8,197
8,486
12,169
12,486
12,540
12,930
17,067
17,092
13,241
16,222
16,152
13,304
13,166
13,16613,30416,15216,22213,24117,09217,06712,93012,54012,48612,1698,4868,1977,5705,3134,0354,5505,8484,2155173,2512,4891,48502,0160748
   > Long-term Liabilities 
0
0
2,050
0
2,050
2,050
2,274
4,183
4,030
3,753
3,877
3,901
5,614
6,906
6,676
5,699
4,177
3,775
4,802
4,533
4,332
4,002
3,951
3,696
3,482
6,922
6,756
6,7566,9223,4823,6963,9514,0024,3324,5334,8023,7754,1775,6996,6766,9065,6143,9013,8773,7534,0304,1832,2742,0502,05002,05000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
2,133
1,980
1,821
1,714
1,543
1,399
2,517
2,013
1,515
988
654
1,851
1,598
1,302
1,019
899
629
416
725
517
5177254166298991,0191,3021,5981,8516549881,5152,0132,5171,3991,5431,7141,8211,9802,1330000000
       Long-term Liabilities Other 
0
0
0
0
0
2,050
2,274
2,133
4,030
3,753
242
457
1,729
6,906
6,676
5,699
939
3,775
4,802
4,533
780
4,002
802
3,696
3,482
822
864
8648223,4823,6968024,0027804,5334,8023,7759395,6996,6766,9061,7294572423,7534,0302,1332,2742,05000000
       Deferred Long Term Liability 
0
772
772
1,263
1,263
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,2631,2637727720
> Total Stockholder Equity
12,061
82,152
82,152
82,152
65,521
155,028
140,527
125,513
108,382
85,939
198,903
175,330
146,008
116,512
105,836
252,217
234,316
210,845
180,106
157,472
131,396
107,898
109,221
107,829
104,681
100,150
100,985
100,985100,150104,681107,829109,221107,898131,396157,472180,106210,845234,316252,217105,836116,512146,008175,330198,90385,939108,382125,513140,527155,02865,52182,15282,15282,15212,061
   Common Stock
2
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
444444444444444443333333332
   Retained Earnings Total Equity00-448,735-442,4330-437,200-409,674-368,543-340,475-303,582-274,724-251,787-285,200-265,267-232,435-192,042-165,900-142,727-118,805-100,769-84,835-70,77500000
   Accumulated Other Comprehensive Income 
0
0
-169
0
-88
-48
7
63
-3
131
50
75
-16
-28
-526
-91
-13
225
1,371
1,682
3,104
4,702
1,331
1,025
1,043
1,849
449
4491,8491,0431,0251,3314,7023,1041,6821,371225-13-91-526-28-167550131-3637-48-880-16900
   Capital Surplus 
0
0
0
0
0
225,848
225,352
226,216
227,187
228,532
364,712
367,293
378,455
381,803
391,558
504,091
509,049
514,198
519,206
524,329
537,962
540,392
0
549,233
552,369
0
0
00552,369549,2330540,392537,962524,329519,206514,198509,049504,091391,558381,803378,455367,293364,712228,532227,187226,216225,352225,84800000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
30
-169
123,879
-88
124,955
225,848
225,352
226,216
227,187
228,532
364,712
367,293
378,455
381,803
391,558
504,091
509,049
514,198
519,206
524,329
537,962
540,392
543,929
549,233
552,369
554,779
558,002
558,002554,779552,369549,233543,929540,392537,962524,329519,206514,198509,049504,091391,558381,803378,455367,293364,712228,532227,187226,216225,352225,848124,955-88123,879-16930



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue84,819
Cost of Revenue-11,416
Gross Profit73,40373,403
 
Operating Income (+$)
Gross Profit73,403
Operating Expense-94,593
Operating Income-21,190-21,190
 
Operating Expense (+$)
Research Development50,873
Selling General Administrative44,514
Selling And Marketing Expenses0
Operating Expense94,59395,387
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-4,710
Net Interest Income4,710
 
Pretax Income (+$)
Operating Income-21,190
Net Interest Income4,710
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,866-21,514
EBIT - interestExpense = -21,190
-20,866
-21,427
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-21,190-20,866
Earnings Before Interest and Taxes (EBITDA)-20,455
 
After tax Income (+$)
Income Before Tax-20,866
Tax Provision-561
Net Income From Continuing Ops-19,282-21,427
Net Income-21,427
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses106,009
Total Other Income/Expenses Net324-4,710
 

Technical Analysis of Y mAbs Therapeutics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Y mAbs Therapeutics. The general trend of Y mAbs Therapeutics is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Y mAbs Therapeutics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Y mAbs Therapeutics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 17.26 < 17.49 < 20.48.

The bearish price targets are: 13.66 > 13.34 > 11.70.

Tweet this
Y mAbs Therapeutics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Y mAbs Therapeutics. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Y mAbs Therapeutics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Y mAbs Therapeutics. The current macd is -0.19526033.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Y mAbs Therapeutics price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Y mAbs Therapeutics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Y mAbs Therapeutics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Y mAbs Therapeutics Daily Moving Average Convergence/Divergence (MACD) ChartY mAbs Therapeutics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Y mAbs Therapeutics. The current adx is 14.08.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Y mAbs Therapeutics shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Y mAbs Therapeutics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Y mAbs Therapeutics. The current sar is 16.23.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Y mAbs Therapeutics Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Y mAbs Therapeutics. The current rsi is 50.54. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Y mAbs Therapeutics Daily Relative Strength Index (RSI) ChartY mAbs Therapeutics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Y mAbs Therapeutics. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Y mAbs Therapeutics price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Y mAbs Therapeutics Daily Stochastic Oscillator ChartY mAbs Therapeutics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Y mAbs Therapeutics. The current cci is -3.95332618.

Y mAbs Therapeutics Daily Commodity Channel Index (CCI) ChartY mAbs Therapeutics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Y mAbs Therapeutics. The current cmo is 4.78622801.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Y mAbs Therapeutics Daily Chande Momentum Oscillator (CMO) ChartY mAbs Therapeutics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Y mAbs Therapeutics. The current willr is -57.34939759.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Y mAbs Therapeutics is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Y mAbs Therapeutics Daily Williams %R ChartY mAbs Therapeutics Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Y mAbs Therapeutics.

Y mAbs Therapeutics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Y mAbs Therapeutics. The current atr is 0.97677473.

Y mAbs Therapeutics Daily Average True Range (ATR) ChartY mAbs Therapeutics Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Y mAbs Therapeutics. The current obv is 24,345,253.

Y mAbs Therapeutics Daily On-Balance Volume (OBV) ChartY mAbs Therapeutics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Y mAbs Therapeutics. The current mfi is 56.07.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Y mAbs Therapeutics Daily Money Flow Index (MFI) ChartY mAbs Therapeutics Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Y mAbs Therapeutics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Y mAbs Therapeutics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Y mAbs Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.543
Ma 20Greater thanMa 5015.185
Ma 50Greater thanMa 10015.568
Ma 100Greater thanMa 20011.811
OpenGreater thanClose15.140
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Y mAbs Therapeutics with someone you think should read this too:
  • Are you bullish or bearish on Y mAbs Therapeutics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Y mAbs Therapeutics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Y mAbs Therapeutics

I send you an email if I find something interesting about Y mAbs Therapeutics.


Comments

How you think about this?

Leave a comment

Stay informed about Y mAbs Therapeutics.

Receive notifications about Y mAbs Therapeutics in your mailbox!